GlaxoSmithKline Pharmaceuticals Valuation
| GLAXO Stock | 2,414 28.15 1.18% |
At this time, the firm appears to be fairly valued. GlaxoSmithKline Pharmaceuticals retains a regular Real Value of USD2341.19 per share. The prevalent price of the firm is USD2413.6. Our model calculates the value of GlaxoSmithKline Pharmaceuticals from evaluating the firm fundamentals such as return on equity of 0.42, and Return On Asset of 0.17 as well as inspecting its technical indicators and probability of bankruptcy.
Price Book 24.1593 | Enterprise Value 382.3 B | Enterprise Value Ebitda 38.249 | Price Sales 11.4838 | Trailing PE 60.5823 |
Fairly Valued
Today
Please note that GlaxoSmithKline Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of GlaxoSmithKline Pharmaceuticals is based on 3 months time horizon. Increasing GlaxoSmithKline Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GlaxoSmithKline Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GlaxoSmithKline Stock. However, GlaxoSmithKline Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2413.6 | Real 2341.19 | Hype 2402.84 | Naive 2416.3 |
The intrinsic value of GlaxoSmithKline Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GlaxoSmithKline Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GlaxoSmithKline Pharmaceuticals Limited helps investors to forecast how GlaxoSmithKline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GlaxoSmithKline Pharmaceuticals more accurately as focusing exclusively on GlaxoSmithKline Pharmaceuticals' fundamentals will not take into account other important factors: GlaxoSmithKline Pharmaceuticals Cash |
|
GlaxoSmithKline Pharmaceuticals Total Value Analysis
GlaxoSmithKline Pharmaceuticals Limited is currently forecasted to have takeover price of 382.29 B with market capitalization of 408.88 B, debt of 186.65 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GlaxoSmithKline Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
382.29 B | 408.88 B | 186.65 M |
GlaxoSmithKline Pharmaceuticals Investor Information
About 76.0% of the company shares are held by company insiders. The company recorded earning per share (EPS) of 39.84. GlaxoSmithKline Pharmaceuticals last dividend was issued on the 7th of November 2024. The entity had 2:1 split on the 11th of September 2018. Based on the key indicators related to GlaxoSmithKline Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, GlaxoSmithKline Pharmaceuticals Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 4.3 B | 5.8 B |
|
| |||||
| Operating Income | 7.4 B | 13.6 B |
|
|
GlaxoSmithKline Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GlaxoSmithKline Pharmaceuticals has an asset utilization ratio of 97.11 percent. This suggests that the Company is making USD0.97 for each dollar of assets. An increasing asset utilization means that GlaxoSmithKline Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.GlaxoSmithKline Pharmaceuticals Ownership Allocation
GlaxoSmithKline Pharmaceuticals Limited has a total of 169.41 Million outstanding shares. GlaxoSmithKline Pharmaceuticals retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 75.58 (percent) of GlaxoSmithKline Pharmaceuticals outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GlaxoSmithKline Pharmaceuticals Profitability Analysis
The company reported the revenue of 34.54 B. Net Income was 5.9 B with profit before overhead, payroll, taxes, and interest of 19 B.About GlaxoSmithKline Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of GlaxoSmithKline Pharmaceuticals Limited. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of GlaxoSmithKline Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing GlaxoSmithKline Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of GlaxoSmithKline Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of GlaxoSmithKline Pharmaceuticals. We calculate exposure to GlaxoSmithKline Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GlaxoSmithKline Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 20.3 B | 15.6 B |
GlaxoSmithKline Pharmaceuticals Quarterly Retained Earnings |
|
Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline Pharmaceuticals financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline Pharmaceuticals security.